ERBB2 and neoplasm: In accordance with the imaging and survival results, we found that ErbB2CAR IP treatments at both low and high doses resulted in a reduction in ErbB2-positive tumor cells in the ovary, and that the outcome was related with low numbers of ErbB2-expressing cells.